Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury Biotech Investing
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress Life Science Investing
Shire Granted EU Marketing Authorization for Veyvondi for Adults With Von Willebrand Disease Biotech Investing
U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process Life Science Investing
Nemaura Reports Positive Interim Data from Clinic Portion of SugarBEAT FDA Clinical Trial Medical Device Investing
FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals Life Science Investing
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival Biotech Investing
Phivida Introduces Premium Active Hemp Extract Infused Functional Beverage and Supplement Line to Mainstream Retailers in the U.S. Cannabis Investing News
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
